Overview

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Gefitinib

Criteria

Inclusion Criteria:

- Failure of either first-line and/or second-line chemotherapy either of which was
platinum-based (the prior regimen must have failed the subject because of toxicity or
progression of tumor

- Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV)
NSCLC

Exclusion Criteria:

- Subjects who have received second-line or subsequent chemotherapy

- Any evidence of clinically active interstitial lung disease (patients with chronic,
stable, radiographic changes who are asymptomatic, need not be excluded)